vs

Side-by-side financial comparison of LAKELAND FINANCIAL CORP (LKFN) and RECURSION PHARMACEUTICALS, INC. (RXRX). Click either name above to swap in a different company.

LAKELAND FINANCIAL CORP is the larger business by last-quarter revenue ($69.7M vs $35.5M, roughly 2.0× RECURSION PHARMACEUTICALS, INC.). LAKELAND FINANCIAL CORP runs the higher net margin — 38.0% vs -304.2%, a 342.2% gap on every dollar of revenue. Over the past eight quarters, RECURSION PHARMACEUTICALS, INC.'s revenue compounded faster (60.5% CAGR vs 0.7%).

Amscot Financial is an American financial services company headquartered in Tampa, Florida. Founded in 1989 by Ian MacKechnie, Amscot Financial provides non-bank consumer financial services through a network of retail branches located exclusively within Florida. Amscot's core services include check cashing, bill payment, prepaid access cards, payday loans, free money orders, ATMs in every branch, wire transfers, notary services, fax services, and postage. Amscot Financial operates nearly 240 ...

Recursion Pharmaceuticals is a clinical-stage biotechnology company that combines artificial intelligence and large-scale high-throughput biological experimentation to discover and develop innovative therapies for rare diseases, oncology, inflammatory disorders, and other areas of unmet medical need. It primarily operates in North America and partners with global biopharmaceutical firms to advance its robust therapeutic pipeline.

LKFN vs RXRX — Head-to-Head

Bigger by revenue
LKFN
LKFN
2.0× larger
LKFN
$69.7M
$35.5M
RXRX
Higher net margin
LKFN
LKFN
342.2% more per $
LKFN
38.0%
-304.2%
RXRX
Faster 2-yr revenue CAGR
RXRX
RXRX
Annualised
RXRX
60.5%
0.7%
LKFN

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LKFN
LKFN
RXRX
RXRX
Revenue
$69.7M
$35.5M
Net Profit
$26.5M
$-108.1M
Gross Margin
59.8%
Operating Margin
-304.8%
Net Margin
38.0%
-304.2%
Revenue YoY
681.7%
Net Profit YoY
31.8%
39.6%
EPS (diluted)
$1.04
$-0.17

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LKFN
LKFN
RXRX
RXRX
Q1 26
$69.7M
Q4 25
$69.8M
$35.5M
Q3 25
$69.0M
$5.2M
Q2 25
$66.4M
$19.2M
Q1 25
$63.8M
$14.7M
Q4 24
$63.6M
$4.5M
Q3 24
$61.2M
$26.1M
Q2 24
$68.7M
$14.4M
Net Profit
LKFN
LKFN
RXRX
RXRX
Q1 26
$26.5M
Q4 25
$29.9M
$-108.1M
Q3 25
$26.4M
$-162.3M
Q2 25
$27.0M
$-171.9M
Q1 25
$20.1M
$-202.5M
Q4 24
$24.2M
$-178.9M
Q3 24
$23.3M
$-95.8M
Q2 24
$22.5M
$-97.5M
Gross Margin
LKFN
LKFN
RXRX
RXRX
Q1 26
Q4 25
59.8%
Q3 25
-183.8%
Q2 25
-4.9%
Q1 25
-48.0%
Q4 24
-181.4%
Q3 24
53.7%
Q2 24
36.2%
Operating Margin
LKFN
LKFN
RXRX
RXRX
Q1 26
Q4 25
52.1%
-304.8%
Q3 25
46.4%
-3327.6%
Q2 25
49.6%
-916.8%
Q1 25
38.0%
-1297.9%
Q4 24
46.0%
-4042.4%
Q3 24
45.3%
-377.1%
Q2 24
39.2%
-697.4%
Net Margin
LKFN
LKFN
RXRX
RXRX
Q1 26
38.0%
Q4 25
42.8%
-304.2%
Q3 25
38.3%
-3135.3%
Q2 25
40.6%
-894.2%
Q1 25
31.5%
-1373.3%
Q4 24
38.1%
-3935.5%
Q3 24
38.1%
-367.5%
Q2 24
32.8%
-676.6%
EPS (diluted)
LKFN
LKFN
RXRX
RXRX
Q1 26
$1.04
Q4 25
$1.16
$-0.17
Q3 25
$1.03
$-0.36
Q2 25
$1.04
$-0.41
Q1 25
$0.78
$-0.50
Q4 24
$0.94
$-0.56
Q3 24
$0.91
$-0.34
Q2 24
$0.87
$-0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LKFN
LKFN
RXRX
RXRX
Cash + ST InvestmentsLiquidity on hand
$85.6M
$743.3M
Total DebtLower is stronger
$183.6M
$9.6M
Stockholders' EquityBook value
$749.0M
$1.1B
Total Assets
$7.1B
$1.5B
Debt / EquityLower = less leverage
0.25×
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LKFN
LKFN
RXRX
RXRX
Q1 26
$85.6M
Q4 25
$141.3M
$743.3M
Q3 25
$192.8M
$659.8M
Q2 25
$310.2M
$525.1M
Q1 25
$235.2M
$500.5M
Q4 24
$168.2M
$594.4M
Q3 24
$160.2M
$427.6M
Q2 24
$121.2M
$474.3M
Total Debt
LKFN
LKFN
RXRX
RXRX
Q1 26
$183.6M
Q4 25
$9.6M
Q3 25
$11.9M
Q2 25
$14.2M
Q1 25
$16.4M
Q4 24
$19.0M
Q3 24
$30.0M
$20.5M
Q2 24
$55.0M
$22.9M
Stockholders' Equity
LKFN
LKFN
RXRX
RXRX
Q1 26
$749.0M
Q4 25
$762.4M
$1.1B
Q3 25
$747.4M
$1.0B
Q2 25
$709.9M
$919.1M
Q1 25
$694.4M
$933.9M
Q4 24
$683.8M
$1.0B
Q3 24
$699.1M
$524.6M
Q2 24
$654.5M
$584.4M
Total Assets
LKFN
LKFN
RXRX
RXRX
Q1 26
$7.1B
Q4 25
$7.0B
$1.5B
Q3 25
$6.9B
$1.4B
Q2 25
$7.0B
$1.3B
Q1 25
$6.9B
$1.3B
Q4 24
$6.7B
$1.4B
Q3 24
$6.6B
$726.5M
Q2 24
$6.6B
$775.9M
Debt / Equity
LKFN
LKFN
RXRX
RXRX
Q1 26
0.25×
Q4 25
0.01×
Q3 25
0.01×
Q2 25
0.02×
Q1 25
0.02×
Q4 24
0.02×
Q3 24
0.04×
0.04×
Q2 24
0.08×
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LKFN
LKFN
RXRX
RXRX
Operating Cash FlowLast quarter
$-46.1M
Free Cash FlowOCF − Capex
$-47.3M
FCF MarginFCF / Revenue
-133.1%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-378.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LKFN
LKFN
RXRX
RXRX
Q1 26
Q4 25
$114.9M
$-46.1M
Q3 25
$36.1M
$-117.4M
Q2 25
$16.2M
$-76.4M
Q1 25
$28.9M
$-132.0M
Q4 24
$102.5M
$-115.4M
Q3 24
$18.0M
$-59.2M
Q2 24
$21.0M
$-82.2M
Free Cash Flow
LKFN
LKFN
RXRX
RXRX
Q1 26
Q4 25
$103.8M
$-47.3M
Q3 25
$31.1M
$-117.6M
Q2 25
$14.1M
$-79.6M
Q1 25
$27.1M
$-133.8M
Q4 24
$93.9M
$-116.7M
Q3 24
$15.3M
$-63.8M
Q2 24
$18.6M
$-83.4M
FCF Margin
LKFN
LKFN
RXRX
RXRX
Q1 26
Q4 25
148.7%
-133.1%
Q3 25
45.0%
-2272.5%
Q2 25
21.2%
-413.9%
Q1 25
42.5%
-907.4%
Q4 24
147.6%
-2567.7%
Q3 24
25.0%
-244.6%
Q2 24
27.0%
-578.5%
Capex Intensity
LKFN
LKFN
RXRX
RXRX
Q1 26
Q4 25
15.9%
3.5%
Q3 25
7.3%
4.7%
Q2 25
3.2%
16.4%
Q1 25
2.8%
12.4%
Q4 24
13.6%
28.6%
Q3 24
4.4%
17.5%
Q2 24
3.5%
8.2%
Cash Conversion
LKFN
LKFN
RXRX
RXRX
Q1 26
Q4 25
3.84×
Q3 25
1.37×
Q2 25
0.60×
Q1 25
1.44×
Q4 24
4.24×
Q3 24
0.77×
Q2 24
0.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LKFN
LKFN

Net Interest Income$56.8M81%
Noninterest Income$12.9M19%

RXRX
RXRX

Segment breakdown not available.

Related Comparisons